EXTON, Penn.--(BUSINESS WIRE)-- The new dialysis bundled payment system that went into effect on January 1, 2011 has had a significant impact on the management of renal anemia according to a number of recently published BioTrends reports, and while bundling has had less impact on the bone and mineral metabolism market, it appears that changes are occurring.
Based on patient-level audit data collected in March 2011, a number of key changes in the management of secondary hyperparathyroidism in the dialysis setting have occurred compared to the prior year, seemingly in an effort to save costs. There have been significant brand shifts among hemodialysis patients treated with active vitamin D compared to last year -- Abbott’s Zemplar has been hit the hardest and the older-generation vitamin D, Calcijex, has benefited the most. Another big change from last year is the percent of active vitamin D-treated hemodialysis patients on oral vs. intravenous (IV) formulations. While IV remains the formulation for the majority of hemodialysis patients, there has been a more than seven-fold increase in the percent of hemodialysis patients treated with oral active vitamin D formulations compared to the prior year. There are differences, however, based on where patients receive dialysis (e.g., large dialysis organizations, small and medium chains, and independent units), with certain units more apt to try oral active vitamin D compared to others. While overall treatment prevalence is similar to last year, the mean weekly dose for both Zemplar IV and Genzyme’s Hectorol IV has decreased.
Phosphate binders and Amgen’s Sensipar, both excluded from the bundle until 2014, appear to be less impacted by bundling to date. Although some expected Sensipar to benefit from its bundle exclusion, the percent of hemodialysis patients treated with Sensipar has not changed compared to the prior year. This may be due in part to the liberalization of PTH goals implemented by a number of dialysis units. While phosphate binder brand use and dose have not changed compared to last year, the BioTrends audit continues to see declining trends in the percent of hemodialysis patients treated with phosphate binders.
ChartTrends®: Bone and Mineral in Dialysis (US) is a syndicated annual report series, in which over 200 nephrologists provide patient chart data on 1,000 dialysis patients in the US to uncover the actual management related to bone and mineral metabolism. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.
About BioTrends Research Group, LLC
BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or http://www.bio-trends.com.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Biotechnology Medical Devices Other Health Research Medical Supplies Science